by Letisia Marquez – City of Hope –
Treating prostate cancer with immunotherapy is currently difficult to do. But preliminary results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope® in patients with advanced prostate cancer showed promise, with minimal side effects. The study published today in Nature Medicine.
